Bemiparin: A Comprehensive Pharmacological and Clinical Monograph

Section 1: Executive Summary & Drug Identification

1.1. Overview of Bemiparin as a Second-Generation Low Molecular Weight Heparin (LMWH)

Bemiparin is a potent antithrombotic agent belonging to the class of low molecular weight heparins (LMWHs).[1] It is distinguished as a second-generation, or ultra-low molecular weight heparin (ultra-LMWH), a classification defined by a unique and optimized pharmacological profile.[3] This profile is characterized by three key features that set it apart from both unfractionated heparin (UFH) and first-generation LMWHs: the lowest mean molecular weight among its peers (approximately 3,600 Daltons), the longest elimination half-life (5 to 6 hours), and the highest ratio of anti-Factor Xa to anti-Factor IIa activity (approximately 8:1).[2] These properties collectively result in a highly predictable anticoagulant response, a favorable efficacy-to-safety balance, and the clinical convenience of a once-daily subcutaneous dosing regimen for its primary indications.[8] Bemiparin is principally used for the prophylaxis and treatment of venous thromboembolism (VTE) and for the prevention of clotting in extracorporeal circuits during hemodialysis.[2]

1.2. Key Identifiers

For the purpose of unambiguous identification in clinical, regulatory, and research contexts, Bemiparin is defined by the following identifiers:

• Generic Name: Bemiparin; Bemiparin Sodium [1]
• DrugBank ID: DB09258 [4]
• CAS Number: 91449-79-5 [5]
• Type: Small Molecule [4]
• ATC Code: B01AB12 (Heparin group) [10]
• International Brand Names: Hibor, Ivor, Zibor, Badyket [3]

1.3. Primary Therapeutic Class and Distinguishing Features